Eric Chatelain
Eric Chatelain
Head of Drug Discovery, Drugs for Neglected Diseases initiative
Verified email at - Homepage
Cited by
Cited by
p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells
H Sutterlüty, E Chatelain, A Marti, C Wirbelauer, M Senften, U Müller, ...
Nature cell biology 1 (4), 207-214, 1999
In vitro and in vivo experimental models for drug screening and development for Chagas disease
AJ Romanha, SL Castro, MNC Soeiro, J Lannes-Vieira, I Ribeiro, ...
Memórias do Instituto Oswaldo Cruz 105, 233-238, 2010
Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?
LH Freitas-Junior, E Chatelain, HA Kim, JL Siqueira-Neto
International Journal for Parasitology: Drugs and Drug Resistance 2, 11-19, 2012
Chagas disease drug discovery: toward a new era
E Chatelain
Journal of biomolecular screening 20 (1), 22-35, 2015
Photostabilization of Butyl methoxydibenzoylmethane (Avobenzone) and Ethylhexyl methoxycinnamate by Bis‐ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), a New UV …
E Chatelain, B Gabard
Photochemistry and photobiology 74 (3), 401-406, 2001
Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols
E Chatelain, DO Boscoboinik, GM Bartoli, VE Kagan, FK Gey, L Packer, ...
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1176 (1-2), 83-89, 1993
Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and …
CB Moraes, MA Giardini, H Kim, CH Franco, AM Araujo-Junior, ...
Scientific reports 4 (1), 4703, 2014
Drug discovery and development for neglected diseases: the DNDi model
E Chatelain, JR Ioset
Drug design, development and therapy, 175-181, 2011
Chagas disease research and development: Is there light at the end of the tunnel?
E Chatelain
Computational and structural biotechnology journal 15, 98-103, 2017
Skin penetration and sun protection factor of five UV filters: effect of the vehicle
E Chatelain, B Gabard, C Surber
Skin Pharmacology and Physiology 16 (1), 28-35, 2003
An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages
JL Siqueira-Neto, S Moon, J Jang, G Yang, C Lee, HK Moon, E Chatelain, ...
PLoS neglected tropical diseases 6 (6), e1671, 2012
Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds
JL Siqueira-Neto, OR Song, H Oh, JH Sohn, G Yang, J Nam, J Jang, ...
PLoS neglected tropical diseases 4 (5), e675, 2010
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging
AF Francisco, MD Lewis, S Jayawardhana, MC Taylor, E Chatelain, ...
Antimicrobial agents and chemotherapy 59 (8), 4653-4661, 2015
Translational challenges of animal models in Chagas disease drug development: a review
E Chatelain, N Konar
Drug design, development and therapy, 4807-4823, 2015
Novel 3-Nitro-1H-1,2,4-triazole-Based Amides and Sulfonamides as Potential Antitrypanosomal Agents
MV Papadopoulou, WD Bloomer, HS Rosenzweig, E Chatelain, M Kaiser, ...
Journal of medicinal chemistry 55 (11), 5554-5565, 2012
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
R Abdelnabi, CS Foo, D Jochmans, L Vangeel, S De Jonghe, ...
Nature Communications 13 (1), 719, 2022
Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign
ML Sykes, JB Baell, M Kaiser, E Chatelain, SR Moawad, D Ganame, ...
PLoS neglected tropical diseases 6 (11), e1896, 2012
Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity
TY Hargrove, Z Wawrzak, PW Alexander, JH Chaplin, M Keenan, ...
Journal of Biological Chemistry 288 (44), 31602-31615, 2013
Phenotypic screening approaches for Chagas disease drug discovery
E Chatelain, JR Ioset
Expert opinion on drug discovery 13 (2), 141-153, 2018
Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease
M Keenan, MJ Abbott, PW Alexander, T Armstrong, WM Best, B Berven, ...
Journal of medicinal chemistry 55 (9), 4189-4204, 2012
The system can't perform the operation now. Try again later.
Articles 1–20